FGEN FibroGen Inc

46.43
+0.83  (+2%)
Previous Close 45.6
Open 45.93
Price To Book 8.19
Market Cap 4,003,286,439
Shares 86,221,978
Volume 333,727
Short Ratio
Av. Daily Volume 912,476

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 MACE safety data released May 9, 2019. Non-inferior in non-dialysis, no worse risk than placebo. NDA filing due September/October 2019.
Roxadustat
Anaemia in Chronic Kidney Disease
Phase 3 data due 2020.
Roxadustat
Myelodysplastic syndromes (MDS)
Phase 2 initial data released June 28, 2019.
FG-3019
Duchenne muscular dystrophy
Phase 2 ongoing in Hong Kong. Future development uncertain
FG-3019
Liver fibrosis
Phase 3 trial to commence 2Q 2019.
Pamrevlumab (FG-3019)
Idiopathic pulmonary fibrosis
Phase 3 trial to be initiated 2Q 2019.
Pamrevlumab (FG-3019)
Pancreatic cancer
Phase 3 Japan data noted hepcidin reduction from baseline (p=0.003) compared to epoetin alfa group (p=0.12)
Roxadustat
Chronic kidney disease

Latest News

  1. Shareholders Are Thrilled That The FibroGen (NASDAQ:FGEN) Share Price Increased 165%
  2. FibroGen to Present Interim Phase 2 Data on Pamrevlumab in Subjects with Duchenne Muscular Dystrophy at the Parent Project Muscular Dystrophy 2019 Annual Conference
  3. See what the IHS Markit Score report has to say about FibroGen Inc.
  4. Here’s What Hedge Funds Think About FibroGen Inc (FGEN)
  5. Can We See Significant Institutional Ownership On The FibroGen, Inc. (NASDAQ:FGEN) Share Register?
  6. FibroGen to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
  7. FibroGen Appoints Suzanne Blaug to Board of Directors
  8. Implied Volatility Surging for FibroGen (FGEN) Stock Options
  9. FibroGen INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In FibroGen, Inc. To Contact The Firm
  10. Edited Transcript of FGEN earnings conference call or presentation 9-May-19 9:00pm GMT
  11. FibroGen Inc (FGEN) Q1 2019 Earnings Call Transcript
  12. Here's Why FibroGen Fell as Much as 26.6% Today
  13. FibroGen News: Why FGEN Stock Is Plummeting Today
  14. The Daily Biotech Pulse: FibroGen Kidney Disease Trial Disappoints, Medtronic To Buy Titan Spine, Puma's Weak Breast Cancer Drug Sales
  15. FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates
  16. FibroGen: 1Q Earnings Snapshot
  17. FibroGen Reports First Quarter 2019 Financial Results
  18. FibroGen Announces Positive Topline Results from Pooled Safety Analyses of Roxadustat Global Phase 3 Program